Blue Jet Healthcare Limited (BLUEJET)
Analysts/Institutional Investor Meet/Con. Call Updates
Analyst presentation on Q1 FY27 financial results
- Revenue ₹2,931mn (+25% QoQ, -17% YoY); EBITDA ₹981mn (33% margin, +38% QoQ, -19% YoY); PAT ₹783mn (27% margin, +22% QoQ, -14% YoY)
- Revenue growth driven by Pharma Intermediates & API segment
- R&D center in Hyderabad to be operational by Sept 2026; Vizag project commenced
- Raised ₹8,000mn via QIP at ₹506/share
- Awarded EcoVadis Silver Medal for sustainability practices
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 BLUEJET — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add BLUEJET to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Blue Jet Healthcare Limited
Important.
The summary above is generated automatically from Blue Jet Healthcare Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.